Fadi Bedros, MD
Nephrology · Manhattan, KSNPI 1407893290
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.8%), food and beverage and education — rather than concentrated in one kind of arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.8%.
Across 101 payments — averaging $69.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$2K
- Novo Nordisk AS$2K
- Vantive US Healthcare LLC$2K
- Vifor Pharma, Inc.$475
- AstraZeneca$392
- Travere Therapeutics, Inc.$272
- plus $1K from 16 others
Across 3 payments — averaging $23,668 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$37K
- AstraZeneca$34K
What the payments were for
- Travel & lodging$3,77754%
- Food & beverage$3,22146%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 9 | $1,673 |
| Novo Nordisk AS | 4 | $1,629 |
| Vantive US Healthcare LLC | 12 | $1,564 |
| Vifor Pharma, Inc. | 23 | $475 |
| AstraZeneca(2 entities) | 18 | $392 |
| Travere Therapeutics, Inc. | 4 | $272 |
| Baxter Healthcare | 3 | $149 |
| Akebia Therapeutics Inc | 3 | $146 |
| Bayer | 4 | $136 |
| Nxstage Medical, Inc. | 3 | $136 |
| Sanofi | 1 | $98 |
| Ardelyx, Inc. | 1 | $68 |
| Calliditas Therapeutics US Inc. | 1 | $41 |
| Boehringer Ingelheim | 2 | $41 |
| Rockwell Medical, Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $33 |
| OPKO Pharmaceuticals, LLC | 2 | $32 |
| Fresenius USA Marketing, Inc. | 2 | $32 |
| GSK | 2 | $30 |
| Novartis | 1 | $17 |
| Amgen | 1 | $16 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - Chronic$1,379
- AURYXIA$123
- Vafseo$123
How this compares
$7,027 in reported general payments places this provider in the 80th percentile of 55 nephrology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 91 | $61,703 |
| JardianceEmpagliflozin | 35 | $23,579 |
| VeltassaPatiromer Calcium Sorbitex | 19 | $12,353 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 52 | $11,537 |
| EliquisApixaban | 13 | $3,859 |
| Calcium Acetate | 30 | $2,765 |
| Sevelamer Carbonate | 18 | $2,256 |
| Calcitriol | 91 | $1,275 |
| Allopurinol | 139 | $1,243 |
| Losartan Potassium | 117 | $1,086 |
| Lisinopril | 182 | $1,017 |
| Tacrolimus | 16 | $787 |
| Metoprolol Succinate | 59 | $786 |
| Amlodipine Besylate | 165 | $775 |
| Metolazone | 67 | $729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $392 | $61,70391 claims |
| Boehringer IngelheimJardiance | $41 | $23,57935 claims |
| PfizerEliquis | $14 | $3,85913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 55 nephrology providers in Kansas.
Other nephrology in Manhattan
- Edgard WehbeWichita$49K
- Scott SolcherTopeka$46K
- Aditi GuptaKansas City$16K
- Alan YuKansas City$16K
- Ahmad TuffahaKansas City$15K
- Brian PaveySalina$14K
- Diane CibrikKansas City$12K
- Dennis RossWichita$12K
- Achal DesaiShawnee$10K
- Richard SchumacherOlathe$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.